MannKind Corporation develops patient-focused drug therapies and innovative technology solutions.
We specialize in innovative technologies with proven ease-of-use and patient acceptance.
Needle-free, self-administered Inhalation Treatment Systems for both chronic and acute diseases.
Our Technosphere® technology can accommodate a wide variety of APIs required by specific drug therapies.
MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. More
MannKind CEO, Michael Castagna, was recently interviewed on SiriusXM Business Radio Powered by The Wharton School. The show has shared the audio file of the 25-minute interview about Afrezza. Find it here
|Jan 16, 2018||MannKind Corporation to Present at NobleCon14 - Noble Capital Markets' Fourteenth Annual Investor Conference… More|
|Nov 07, 2017||MannKind Corporation Reports 2017 Third Quarter Financial Results… More|
|Oct 27, 2017||MannKind Corporation to Hold 2017 Third Quarter Financial Results Conference Call on November 7, 2017… More|
If you are reporting an Adverse Event and/or device complaint, please contact MannKind Medical Information at 1-877-323-8505 or MannKind@druginfo.com. Do not use this form for adverse events and/or device complaints.